Top 5 Weight Loss Shots: Which One Is Right for You?

In today's fast-paced world, many individuals struggle with weight management, which can significantly impact their overall health and well-being. As a medical professional, I understand the challenges you may face and the desire to find an effective solution. In this article, we will explore the top 5 weight loss shots available on the market, discussing their mechanisms of action, potential benefits, and considerations. My goal is to provide you with the information you need to make an informed decision about which option may be most suitable for your unique needs.

1. Semaglutide (Ozempic, Wegovy)

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has gained significant attention for its weight loss potential. Originally developed for the management of type 2 diabetes, semaglutide has been found to promote weight loss in both diabetic and non-diabetic individuals.

Mechanism of Action: Semaglutide works by mimicking the effects of the GLP-1 hormone, which is naturally produced in the body. It helps regulate blood sugar levels, slows gastric emptying, and promotes a feeling of fullness, leading to reduced food intake and weight loss (1).

Clinical Evidence: In a large-scale clinical trial, semaglutide was shown to result in an average weight loss of 14.9% over 68 weeks in individuals with obesity, compared to 2.4% in the placebo group (2). Another study demonstrated that semaglutide led to a significant reduction in body weight and improved cardiometabolic risk factors in patients with type 2 diabetes (3).

Considerations: Semaglutide is typically administered as a once-weekly injection. Common side effects include nausea, vomiting, and diarrhea, which tend to be mild and transient. It is important to note that semaglutide is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (4).

2. Liraglutide (Saxenda)

Liraglutide is another GLP-1 receptor agonist that has been approved for chronic weight management in adults with obesity or overweight individuals with at least one weight-related comorbidity.

Mechanism of Action: Similar to semaglutide, liraglutide works by mimicking the effects of the GLP-1 hormone, leading to reduced appetite, delayed gastric emptying, and increased satiety (5).

Clinical Evidence: In a 56-week clinical trial, liraglutide was shown to result in an average weight loss of 8.4% compared to 2.8% in the placebo group (6). Another study demonstrated that liraglutide led to significant weight loss and improvements in cardiovascular risk factors in patients with obesity and type 2 diabetes (7).

Considerations: Liraglutide is administered as a once-daily injection. Common side effects include nausea, vomiting, diarrhea, and constipation. As with semaglutide, liraglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (8).

3. Tirzepatide (Mounjaro)

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that has shown promising results in weight loss trials.

Mechanism of Action: Tirzepatide works by activating both GIP and GLP-1 receptors, leading to improved glucose control, reduced appetite, and increased satiety (9).

Clinical Evidence: In a phase 3 clinical trial, tirzepatide resulted in an average weight loss of 22.5% over 72 weeks in individuals with obesity, compared to 2.4% in the placebo group (10). Another study demonstrated that tirzepatide led to significant weight loss and improvements in glycemic control in patients with type 2 diabetes (11).

Considerations: Tirzepatide is administered as a once-weekly injection. Common side effects include nausea, vomiting, and diarrhea, which tend to be mild and transient. As with other GLP-1 receptor agonists, tirzepatide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (12).

4. Phentermine/Topiramate (Qsymia)

Phentermine/topiramate is a combination medication that has been approved for chronic weight management in adults with obesity or overweight individuals with at least one weight-related comorbidity.

Mechanism of Action: Phentermine is a sympathomimetic amine that acts as an appetite suppressant, while topiramate is an anticonvulsant that may also reduce appetite and increase feelings of fullness (13).

Clinical Evidence: In a 56-week clinical trial, phentermine/topiramate resulted in an average weight loss of 10.9% compared to 1.6% in the placebo group (14). Another study demonstrated that phentermine/topiramate led to significant weight loss and improvements in cardiometabolic risk factors in patients with obesity (15).

Considerations: Phentermine/topiramate is taken orally, with the dose gradually increased over time. Common side effects include dry mouth, constipation, and paresthesia. Phentermine/topiramate is contraindicated in individuals with a history of glaucoma, hyperthyroidism, or cardiovascular disease (16).

5. Naltrexone/Bupropion (Contrave)

Naltrexone/bupropion is another combination medication that has been approved for chronic weight management in adults with obesity or overweight individuals with at least one weight-related comorbidity.

Mechanism of Action: Naltrexone is an opioid receptor antagonist, while bupropion is an antidepressant that also acts as a dopamine and norepinephrine reuptake inhibitor. Together, these medications work to reduce appetite and increase satiety (17).

Clinical Evidence: In a 56-week clinical trial, naltrexone/bupropion resulted in an average weight loss of 6.1% compared to 1.3% in the placebo group (18). Another study demonstrated that naltrexone/bupropion led to significant weight loss and improvements in cardiovascular risk factors in patients with obesity (19).

Considerations: Naltrexone/bupropion is taken orally, with the dose gradually increased over time. Common side effects include nausea, constipation, and headache. Naltrexone/bupropion is contraindicated in individuals with a history of seizures, eating disorders, or opioid use (20).

Which Weight Loss Shot Is Right for You?

Choosing the most appropriate weight loss shot depends on various factors, including your medical history, current medications, and personal preferences. As your healthcare provider, I am here to guide you through this decision-making process and ensure that the chosen option aligns with your overall health goals.

Here are some key considerations to keep in mind:

  1. Efficacy: All five weight loss shots have demonstrated significant weight loss in clinical trials. However, the magnitude of weight loss may vary between individuals and medications. Semaglutide and tirzepatide have shown the most impressive results, with average weight losses of 14.9% and 22.5%, respectively (2, 10).

  2. Safety Profile: Each weight loss shot has its own set of potential side effects and contraindications. It is crucial to discuss your medical history and any current medications with your healthcare provider to determine which option is safest for you. For example, if you have a history of thyroid cancer, GLP-1 receptor agonists like semaglutide, liraglutide, and tirzepatide may not be suitable (4, 8, 12).

  3. Administration: The frequency and method of administration may also influence your decision. Semaglutide, tirzepatide, and liraglutide are administered as injections, with semaglutide and tirzepatide being once-weekly and liraglutide being once-daily. On the other hand, phentermine/topiramate and naltrexone/bupropion are taken orally.

  4. Cost and Insurance Coverage: The cost of weight loss shots can vary significantly, and insurance coverage may differ depending on your specific plan. It is essential to discuss these factors with your healthcare provider and insurance company to determine the most cost-effective option for you.

  5. Lifestyle Considerations: While weight loss shots can be effective tools, they should be used in conjunction with a comprehensive weight management plan that includes dietary modifications, increased physical activity, and behavioral changes. It is important to set realistic expectations and understand that these medications are not a magic solution but rather a tool to support your overall weight loss journey.

As your healthcare provider, I am committed to helping you navigate the complex world of weight loss shots. Together, we can determine which option is best suited to your unique needs and circumstances. Remember, you are not alone in this journey, and I am here to support you every step of the way.

Conclusion

Weight loss shots have revolutionized the field of obesity management, offering effective and convenient options for individuals struggling with weight loss. The top 5 weight loss shots discussed in this article—semaglutide, liraglutide, tirzepatide, phentermine/topiramate, and naltrexone/bupropion—have all demonstrated significant weight loss in clinical trials.

However, choosing the right weight loss shot is a highly individualized process that requires careful consideration of various factors, including efficacy, safety, administration, cost, and lifestyle. As your healthcare provider, I am dedicated to helping you make an informed decision that aligns with your overall health goals and supports your long-term success.

Remember, weight loss is a journey, and these medications are just one piece of the puzzle. With the right combination of medical support, lifestyle modifications, and a positive mindset, you can achieve your weight loss goals and improve your overall health and well-being.

References

  1. Nauck, M. A., & Meier, J. J. (2016). The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. The Lancet Diabetes & Endocrinology, 4(6), 525-536.

  2. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.

  3. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., & Perreault, L. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984.

  4. Ozempic (semaglutide) injection [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; 2021.

  5. Vilsbøll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012). Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ, 344, d7771.

  6. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22.

  7. Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., ... & Wadden, T. A. (2015). Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA, 314(7), 687-699.

  8. Saxenda (liraglutide) injection [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; 2021.

  9. Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., ... & Milicevic, Z. (2018). Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. The Lancet, 392(10160), 2180-2193.

  10. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Dungan, K. M. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216.

  11. Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Landó, L. F., ... & Milicevic, Z. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155.

  12. Mounjaro (tirzepatide) injection [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2022.

  13. Gadde, K. M., & Allison, D. B. (2009). Combination therapy for obesity and metabolic disease. Current Opinion in Endocrinology, Diabetes and Obesity, 16(5), 353-358.

  14. Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., ... & Kowalczyk, M. (2012). Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity, 20(2), 330-342.

  15. Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., ... & Schwiers, M. (2012). Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. The American Journal of Clinical Nutrition, 95(2), 297-308.

  16. Qsymia (phentermine and topiramate extended-release) capsules [prescribing information]. Mountain View, CA: Vivus Inc; 2021.

  17. Greenway, F. L., Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M., Fujioka, K., & Cowley, M. A. (2009). Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. The Journal of Clinical Endocrinology & Metabolism, 94(12), 4898-4906.

  18. Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., ... & Dunayevich, E. (2013). A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity, 21(5), 935-943.

  19. Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., ... & Dunayevich, E. (2013). Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care, 36(12), 4022-4029.

  20. Contrave (naltrexone HCl and bupropion HCl) extended-release tablets [prescribing information]. Irvine, CA: Orexigen Therapeutics, Inc; 2021.